Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 11/20 | 0.39 |
| ▸ | F3 | P13726 | 11/20 | 0.39 |
| ▸ | F10 | P00742 | 7/20 | 0.36 |
| ▸ | F2 | P00734 | 6/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861501 | 0.96 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL3858776 | 0.95 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL3862843 | 0.93 | F7 (0.40) | F7F3F10F2F11 | |
| SCHEMBL3860271 | 0.91 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL3861497 | 0.88 | F7 (0.39) | F7F3F10F2F11 | |
| SCHEMBL3858773 | 0.88 | F7 (0.39) | F7F3F10F2F11 | |
| SCHEMBL3866374 | 0.86 | F7 (0.43) | F7F3F10F2F11 | |
| SCHEMBL3860267 | 0.83 | F7 (0.39) | F7F3F10F2F11 | |
| SCHEMBL3864911 | 0.83 | F7 (0.42) | F7F3F10F2F11 | |
| SCHEMBL3865478 | 0.82 | F7 (0.42) | F7F3F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | F7 2/4885F3 10/4885F10 8/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | F7 2/4885F3 10/4885F10 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.